Heyholder
‹ Activism Filings

DONGWHA PHARM.CO.,LTD Q3 profit from main business KRW 3.8 billion on sales of KRW 129.9 billion

DONGWHA PHARM.CO.,LTD· Periodic Report

AI summary · Not investment advice

Dong Wha Pharm sold KRW 129.9 billion in Q3 and earned KRW 3.8 billion from its main business, up 179.5% from a year earlier and down 62.8% from the prior quarter.

Operating profit · 3 months

KRW 3.8 billion

Key facts

Revenue (3 months)
KRW 129.9 billion
Net income (3 months)
KRW 68.1 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 122.0 billion
Revenue (year to date)
KRW 397.5 billion
Operating profit (prior-year 3 months)
KRW 1.4 billion
Operating profit (year to date)
KRW 25.3 billion
Net income (prior-year 3 months)
KRW 241.6 million
Net income (year to date)
KRW 16.2 billion

Commentary

AI commentary · Not investment advice

What happened

Dongwha Pharm reported its consolidated results for the third quarter of 2026 (July to September). Sales for the 3 months were KRW 129.9 billion. That is 6.5% higher than the same 3 months a year earlier and 5.1% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 3.8 billion. That is 179.5% higher than a year earlier and 62.8% lower than the previous quarter.

What changes for shareholders

Net income (the final profit after taxes and other costs) for the 3 months was KRW 68.1 million. That is 71.8% lower than a year earlier and 98.9% lower than the previous quarter.

For the year to date (January 1 to September 30), sales were KRW 397.5 billion. Operating profit was KRW 25.3 billion and net income was KRW 16.2 billion.

Comments

No comments yet

Comments from shareholders will appear here.